AGT and type 2 diabetes mellitus: In 2001, two landmark trials, the IDNT (Irbesartan Diabetic Nephropathy Trial) and RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan), demonstrated that compared with placebo (in IDNT) or active-treatment with a calcium-channel-blocker (in RENAAL), an angiotensin-receptor-blocker was more effective in slowing the progression of CKD in patients with T2DM and overt nephropathy [8,9].